← ANALYST RATINGS · TIPRANKS
Arcutis Biotherapeutics (ARQT): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months · top analysts only12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $39.00, the highest $48.00, the lowest $34.00. The average is +35.3% from the last price of $28.82.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $48.00 | Buy | +66.6% | Initiated | 15.10.26on TipRanks 06:40 | +9.9%next day +0.1% | ↗ |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $26.00 → $29.00+11.5% | Hold | +0.6% | Downgrade | 17.09.26on TipRanks 09:09 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $27.00 → $29.00+7.4% | Buy | +0.6% | Reiterated | 17.09.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $26.00 → $28.00+7.7% | Hold | −2.8% | Downgrade | 17.09.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $24.50 → $28.00+14.3% | Hold | −2.8% | Reiterated | 17.09.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $27.00 → $30.00+11.1% | Buy | +4.1% | Reiterated | 17.09.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $26.00 → $29.00+11.5% | Buy | +0.6% | Reiterated | 17.09.26on TipRanks 06:05 | — | |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $34.00 | Buy | +18.0% | Reiterated | 10.08.26on TipRanks Aug 11 04:08 | +2.5%next day +1.5% · 5 days −1.1% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $34.00 → $38.00+11.8% | Buy | +31.9% | Assigned | 06.08.26on TipRanks 07:11 | −2.3%next day −4.9% · 5 days −3.5% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $40.00 | Buy | +38.8% | Assigned | 06.08.26on TipRanks 06:50 | −2.3%next day −4.9% · 5 days −3.5% | ↗ |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $35.00 → $38.00+8.6% | Buy | +31.9% | Assigned | 05.08.26on TipRanks Aug 6 06:50 | +4.3%next day −2.3% · 5 days −3.4% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | $35.00 | Buy | +21.4% | Reiterated | 05.08.26on TipRanks Aug 6 06:05 | +4.3%next day −2.3% · 5 days −3.4% | ↗ |
| Unknown Analyst | Jefferies | $35.00 | Buy | +21.4% | Reiterated | 09.07.26on TipRanks Jul 11 06:06 | +0.1%next day −4.0% · 5 days −3.5% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $29.00 → $33.00+13.8% | Hold | +14.5% | Reiterated | 27.02.26on TipRanks 07:55 | −5.1%next day −8.3% · 5 days −9.0% | ↗ |
| Kambiz Yazdi★★★★★★★★★★#1181 · hits 67% · avg +24.8% | BTIG | $31.00 | Buy | +7.6% | Reiterated | 15.01.26on TipRanks 08:36 | −1.7%next day −1.9% · 5 days −0.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Arcutis Biotherapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $36.67 at a price of $26.43 (+38.7%); now: $38.83 at $28.82 (+34.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 7 | 2 | 1 | 2 |
| Buy | 6 | 5 | 6 | 9 | 8 | 5 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.18 (from $0.14 to $0.28). Last quarter: $0.11.
Sales
Next quarter’s sales estimate — $143M (from $140M to $147M). Last quarter: $130M.
Best top-analyst consensus in the sector · Healthcare
About Arcutis Biotherapeutics
- CEO: Todd Franklin Watanabe
- Employees: 354
- 3027 Townsgate Road, Westlake Village, CA, 91361, US
- www.arcutis.com
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Data from the stock’s TipRanks forecast page, read 101 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗